Pharmacological Inhibition of Microglial Proliferation Supports Blood–Brain Barrier Integrity in Experimental Autoimmune Encephalomyelitis
Cells · 2025
DOI: 10.3390/cells14060414 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Nozha Borjini und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research & Development, Chiesi Farmaceutici S.p.A, via Palermo 26/A, 43100 Parma, Italy. Hauptthemen laut MEDLINE: Receptors, Granulocyte-Macrophage Colony-Stimulating Factor, Encephalomyelitis, Autoimmune, Experimental, Tyrosine Kinase Inhibitors, Microglia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the European Union's Seventh Framework Program FP7, European Union’s Seventh Framework Program FP7.
Abstract (Originalsprache)
Blood–brain barrier dysfunction (BBB) is a primary characteristic of experimental autoimmune encephalomyelitis (EAE), an experimental model of multiple sclerosis (MS). We have previously shown that blocking microglial proliferation using GW2580, a selective inhibitor of CSF1R (Colony stimulating factor 1 receptor), reduced disease progression and severity and prevented the relapse phase. However, whether this was due to effects of GW2580 on the functional integrity of the BBB was not determined. Therefore, here, we examine BBB properties in rats during EAE under GW2580 treatment. Our data suggest that blocking early microglial proliferation through selective targeting of CSF1R signaling has a therapeutic effect in EAE by protecting BBB integrity and reducing peripheral immune cell infiltration. Taken together, our results identify a novel mechanism underlying the effects of GW2580, which could offer a novel therapy for MS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research & Development, Chiesi Farmaceutici S.p.A, via Palermo 26/A, 43100 Parma, Italy.
- IRET Foundation, via Tolara di Sopra 41/E, Ozzano Emilia, 40064 Bologna, Italy.
- Department de Fisiología Médica y Biofísica, Instituto de Biomedicina de Sevilla (IBiS, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla), 41013 Sevilla, Spain.
- Facultad de Medicina and CIBERNED ISCIII, 41013 Sevilla, Spain.
- Health Science and Technologies Interdepartmental Center for Industrial Research (HST-ICIR), University of Bologna, via Tolara di Sopra 41/E, Ozzano Emilia, 40064 Bologna, Italy.
- Department of Veterinary Medical Sciences, University of Bologna, via Tolara di Sopra 50, Ozzano Emilia (BO), 40064 Bologna, Italy.
ORCID-Profile: Nozha Borjini, Mercedes Fernandez, Laura Calzà
Förderung
- the European Union's Seventh Framework Program FP7
- European Union’s Seventh Framework Program FP7
Zitieren
APA
Borjini, N., Fernandez, M., Giardino, L., Sorokin, L., & Calzà, L. (2025). Pharmacological Inhibition of Microglial Proliferation Supports Blood–Brain Barrier Integrity in Experimental Autoimmune Encephalomyelitis. Cells. https://doi.org/10.3390/cells14060414
Vancouver
Borjini N, Fernandez M, Giardino L, Sorokin L, Calzà L. Pharmacological Inhibition of Microglial Proliferation Supports Blood–Brain Barrier Integrity in Experimental Autoimmune Encephalomyelitis. Cells. 2025. doi:10.3390/cells14060414
BibTeX
@article{Borjini2025,
author = {Borjini, Nozha and Fernandez, Mercedes and Giardino, Luciana and Sorokin, Lydia and Calzà, Laura},
title = {Pharmacological Inhibition of Microglial Proliferation Supports Blood–Brain Barrier Integrity in Experimental Autoimmune Encephalomyelitis},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14060414}
}
EUVIMED